Status:
COMPLETED
Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China
Lead Sponsor:
Daiichi Sankyo
Collaborating Sponsors:
Daiichi Sankyo Co., Ltd.
Conditions:
Diabetic Peripheral Neuropathic Pain
Chemotherapy-induced Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to investigate the pharmacological treatment pattern among patients with diabetic peripheral neuropathic pain (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN) in C...
Detailed Description
Diabetic peripheral neuropathic pain (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN) are common subtypes of neuropathic pain. The treatment pattern, subsequent medication usage, and adher...
Eligibility Criteria
Inclusion
- Participants who meet all the following criteria will be included in the DPNP cohort.
- Participants were diagnosed with diabetic neuropathy and presented with the pain symptom between 1st January 2018 and 31st December 2021;
- Participants received at least one targeted medication between 1st January 2018 and 31st December 2021;
- Participants were ≥18 years on the index date;
- Participants had at least one medical visit record within 12 months after the index date
- Participants who meet any one of the following criteria will be excluded from the DPNP cohort.
- (1) Participants were diagnosed with epilepsy, schizophrenia, or bipolar disorder before or on the index date
- Participants who meet all the following criteria will be included in the CIPN cohort.
- Participants had neuropathy that was induced by the chemotherapy between 1st January 2018 and 31st December 2021, regardless of the presence of pain symptoms;
- Participants received at least one targeted medication between 1st January 2018 and 31st December 2021;
- Participants were ≥18 years on the index date;
- Participants had at least one medical visit record within12 months after the index date
- Participants who meet any one of the following criteria will be excluded from the CIPN cohort.
- Participants were diagnosed with epilepsy, schizophrenia, or bipolar disorder before or on the index date;
- Participants had neuralgia or neuropathy caused by tumor metastasis or non-chemotherapy-induced factors (e.g., radiotherapy, myasthenia gravis syndrome, paraneoplastic syndrome, direct tumor invasion, local tissue compression, postoperative traumatic pain, immune therapy-related pain, comorbidity-induced pain, etc.)
Exclusion
Key Trial Info
Start Date :
August 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 18 2025
Estimated Enrollment :
1271 Patients enrolled
Trial Details
Trial ID
NCT06546202
Start Date
August 16 2024
End Date
July 18 2025
Last Update
July 23 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
China-Japan Friendship Hospital
Beijing, China, 100013
2
Beijing Hospital
Beijing, China, 100051
3
Beijing Cancer Hospital
Beijing, China, 100142
4
The First Affiliated Hospital of Dalian Medical University
Dalian, China, 116011